Pulmonary embolism following placement of a Greenfield Filter.

H. Pullon,P. Ockelford,J. Wattie,P. Charlesworth

DOI: https://doi.org/10.1111/J.1445-5994.1989.TB00326.X

1989-10-01

Australian and New Zealand Journal of Medicine

Abstract:

What problem does this paper attempt to address?

Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

Mev Dominguez-Valentin,Saskia Haupt,Toni T Seppälä,Julian R Sampson,Lone Sunde,Inge Bernstein,Mark A Jenkins,Christoph Engel,Stefan Aretz,Maartje Nielsen,Gabriel Capella,Francesc Balaguer,Dafydd Gareth Evans,John Burn,Elke Holinski-Feder,Lucio Bertario,Bernardo Bonanni,Annika Lindblom,Zohar Levi,Finlay Macrae,Ingrid Winship,John-Paul Plazzer,Rolf Sijmons,Luigi Laghi,Adriana Della Valle,Karl Heinimann,Tadeusz Dębniak,Robert Fruscio,Francisco Lopez-Koestner,Karin Alvarez-Valenzuela,Lior H Katz,Ido Laish,Elez Vainer,Carlos Vaccaro,Dirce Maria Carraro,Kevin Monahan,Elizabeth Half,Aine Stakelum,Des Winter,Rory Kennelly,Nathan Gluck,Harsh Sheth,Naim Abu-Freha,Marc Greenblatt,Benedito Mauro Rossi,Mabel Bohorquez,Giulia Martina Cavestro,Leonardo S Lino-Silva,Karoline Horisberger,Maria Grazia Tibiletti,Ivana do Nascimento,Huw Thomas,Norma Teresa Rossi,Leandro Apolinário da Silva,Attila Zaránd,Juan Ruiz-Bañobre,Vincent Heuveline,Jukka-Pekka Mecklin,Kirsi Pylvänäinen,Laura Renkonen-Sinisalo,Anna Lepistö,Päivi Peltomäki,Christina Therkildsen,Mia Gebauer Madsen,Stefan Kobbelgaard Burgdorf,John L Hopper,Aung Ko Win,Robert W Haile,Noralane Lindor,Steven Gallinger,Loïc Le Marchand,Polly A Newcomb,Jane Figueiredo,Daniel D Buchanan,Stephen N Thibodeau,Magnus von Knebel Doeberitz,Markus Loeffler,Nils Rahner,Evelin Schröck,Verena Steinke-Lange,Wolff Schmiegel,Deepak Vangala,Claudia Perne,Robert Hüneburg,Silke Redler,Reinhard Büttner,Jürgen Weitz,Marta Pineda,Nuria Duenas,Joan Brunet Vidal,Leticia Moreira,Ariadna Sánchez,Eivind Hovig,Sigve Nakken,Kate Green,Fiona Lalloo,James Hill,Emma Crosbie,Miriam Mints,Yael Goldberg,Douglas Tjandra,Sanne W Ten Broeke,Revital Kariv,Guy Rosner,Suresh H Advani,Lidiya Thomas,Pankaj Shah,Mithun Shah,Florencia Neffa,Patricia Esperon,Walter Pavicic,Giovana Tardin Torrezan,Thiago Bassaneze,Claudia Alejandra Martin,Gabriela Moslein,Pål Moller

DOI: https://doi.org/10.1016/j.eclinm.2023.101909

IF: 15.1

2023-03-20

EClinicalMedicine

Abstract:Background: The Prospective Lynch Syndrome Database (PLSD) collates information on carriers of pathogenic or likely pathogenic MMR variants (path_MMR) who are receiving medical follow-up, including colonoscopy surveillance, which aims to the achieve early diagnosis and treatment of cancers. Here we use the most recent PLSD cohort that is larger and has wider geographical representation than previous versions, allowing us to present mortality as an outcome, and median ages at cancer diagnoses for the first time. Methods: The PLSD is a prospective observational study without a control group that was designed in 2012 and updated up to October 2022. Data for 8500 carriers of path_MMR variants from 25 countries were included, providing 71,713 years of follow up. Cumulative cancer incidences at 65 years of age were combined with 10-year crude survival following cancer, to derive estimates of mortality up to 75 years of age by organ, gene, and gender. Findings: Gynaecological cancers were more frequent than colorectal cancers in path_MSH2, path_MSH6 and path_PMS2 carriers [cumulative incidence: 53.3%, 49.6% and 23.3% at 75 years, respectively]. Endometrial, colon and ovarian cancer had low mortality [8%, 13% and 15%, respectively] and prostate cancers were frequent in male path_MSH2 carriers [cumulative incidence: 39.7% at 75 years]. Pancreatic, brain, biliary tract and ureter and kidney and urinary bladder cancers were associated with high mortality [83%, 66%, 58%, 27%, and 29%, respectively]. Among path_MMR carriers undergoing colonoscopy surveillance, particularly path_MSH2 carriers, more deaths followed non-colorectal Lynch syndrome cancers than colorectal cancers. Interpretation: In path_MMR carriers undergoing colonoscopy surveillance, non-colorectal Lynch syndrome cancers were associated with more deaths than were colorectal cancers. Reducing deaths from non-colorectal cancers presents a key challenge in contemporary medical care in Lynch syndrome. Funding: We acknowledge funding from the Norwegian Cancer Society, contract 194751-2017.
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Timothy R. Rebbeck,Tara M. Friebel,Eitan Friedman,Ute Hamann,Dezheng Huo,Ava Kwong,Edith Olah,Olufunmilayo I. Olopade,Angela R. Solano,Soo‐Hwang Teo,Mads Thomassen,Jeffrey N. Weitzel,TL Chan,Fergus J. Couch,David E. Goldgar,Torben A. Kruse,Edenir Inêz Palmero,Sue Kyung Park,Diana Torres,Elizabeth J. Rensburg,Lesley McGuffog,Michael T. Parsons,Goska Leslie,Cora M. Aalfs,Julio Abugattas,Julian Adlard,Simona Agata,Kristiina Aittomäki,Lesley Andrews,Irene L. Andrulis,Adalgeir Arason,Norbert Arnold,Banu K. Arun,Ella Asseryanis,Leo Auerbach,Jacopo Azzollini,Judith Balmaña,Monica Barile,Rosa B. Barkardottir,Daniel Barrowdale,Javier Benitez,Andreas Berger,Raanan Berger,Amie M. Blanco,Kathleen R. Blazer,Marinus J. Blok,Valérie Bonadona,Bernardo Bonanni,Angela R. Bradbury,Carole Brewer,Bruno Buecher,Saundra S. Buys,Trinidad Caldes,Almuth Caliebe,Maria A. Caligo,Ian Campbell,Sandrine M. Caputo,Jocelyne Chiquette,Wendy K. Chung,Kathleen B.M. Claes,J. Margriet Collée,Jackie Cook,Rosemarie Davidson,Miguel la Hoya,Kim Leeneer,Antoine Pauw,Capucine Delnatte,Orland Diez,Yuan Chun Ding,Nina Ditsch,Susan M. Domchek,Cecilia M. Dorfling,Carolina Velazquez,Bernd Dworniczak,Jacqueline Eason,Douglas F. Easton,Ros Eeles,Hans Ehrencrona,Bent Ejlertsen,EMBRACE,Christoph Engel,Stefanie Engert,D. Gareth Evans,Laurence Faivre,Lidia Feliubadaló,Sandra Fert Ferrer,Lenka Foretova,Jeffrey Fowler,Debra Frost,Henrique C. R. Galvão,Patricia A. Ganz,Judy Garber,Marion Gauthier‐Villars,Andrea Gehrig,GEMO Study Collaborators,Anne‐Marie Gerdes,Paul Gesta,Giuseppe Giannini,Sophie Giraud,Gord Glendon,Andrew K. Godwin,Mark H. Greene,Jacek Gronwald,Angelica Gutierrez‐Barrera,Eric Hahnen,Jan Hauke,HEBON,Alex Henderson,Julia Hentschel,Frans B.L. Hogervorst,Ellen Honisch,Evgeny N. Imyanitov,Claudine Isaacs,Louise Izatt,Angel Izquierdo,Anna Jakubowska,Paul James,Ramunas Janavicius,Uffe Birk Jensen,Esther M. John,Joseph Vijai,Katarzyna Kaczmarek,Beth Y. Karlan,Karin Kast,KConFab Investigators,Sung‐Won Kim,Irene Konstantopoulou,Jacob Korach,Yael Laitman,Adriana Lasa,Christine Lasset,Conxi Lázaro,Annette Lee,Min Hyuk Lee,Jenny Lester,Fabienne Lesueur,Annelie Liljegren,Noralane M. Lindor,Michel Longy,Jennifer T. Loud,Karen H. Lu,Jan Lubinski,Eva Machackova,Siranoush Manoukian,Véronique Mari,Cristina Martínez‐Bouzas,Zoltan Matrai,Noura Mebirouk,Hanne E.J. Meijers‐Heijboer,Alfons Meindl,Arjen R. Mensenkamp,Ugnius Mickys,Austin Miller,Marco Montagna,Kirsten B. Moysich,Anna Marie Mulligan,Jacob Musinsky,Susan L. Neuhausen,Heli Nevanlinna,Joanne Ngeow,Huu Phuc Nguyen,Dieter Niederacher,Henriette Roed Nielsen,Finn Cilius Nielsen,Robert L. Nussbaum,Kenneth Offit,Anna Öfverholm,Kai‐ren Ong,Ana Osorio,Laura Papi,Janos Papp,Barbara Pasini,Inge Sokilde Pedersen,Ana Peixoto,Nina Peruga,Paolo Peterlongo,Esther Pohl,Nisha Pradhan,Karolina Prajzendanc,Fabienne Prieur,Pascal Pujol,Paolo Radice,Susan J. Ramus,Johanna Rantala,Muhammad Usman Rashid,Kerstin Rhiem,Mark Robson,Gustavo C. Rodriguez,Mark T. Rogers,Vilius Rudaitis,Ane Y. Schmidt,Rita Katharina Schmutzler,Leigha Senter,Payal D. Shah,Priyanka Sharma,Lucy E. Side,Jacques Simard,Christian F. Singer,Anne‐Bine Skytte,Thomas P. Slavin,Katie Snape,Hagay Sobol,Melissa Southey,Linda Steele,Doris Steinemann,Grzegorz Sukiennicki,Christian Sutter,Csilla I. Szabo,Yen Y. Tan,Manuel R. Teixeira,Mary Beth Terry,Alex Teulé,Abigail Thomas,Darcy L. Thull,Marc Tischkowitz,Silvia Tognazzo,Amanda Ewart Toland,Sabine Topka,Alison H Trainer,Nadine Tung,Christi J. Asperen,Annemieke H. der Hout,Lizet E. der Kolk,Rob B. der Luijt,Mattias Heetvelde,Liliana Varesco,Raymonda Varon‐Mateeva,Ana Vega,Cynthia Villarreal‐Garza,Anna Wachenfeldt,Lisa Walker,Shan Wang‐Gohrke,Barbara Wappenschmidt,Bernhard H. F. Weber,Drakoulis Yannoukakos,Sook‐Yee Yoon,Cristina Zanzottera,Jamal Zidan,Kristin K. Zorn,Christina G. Hutten Selkirk,Peter J. Hulick,Georgia Chenevix‐Trench,Amanda B. Spurdle,Antonis C. Antoniou,Katherine L. Nathanson,Soo-Hwang Teo,Elizabeth J. van Rensburg,Miguel de la Hoya,Kim De Leeneer,Antoine de Pauw,Marion Gauthier-Villars,Anne-Marie Gerdes,Angelica Gutierrez-Barrera,Sung-Won Kim,Cristina Martínez-Bouzas,Hanne E.J. Meijers-Heijboer,Kai-ren Ong,Anne-Bine Skytte,Christi J. van Asperen,Annemieke H. van der Hout,Lizet E. van der Kolk,Rob B. van der Luijt,Mattias Van Heetvelde,Raymonda Varon-Mateeva,Cynthia Villarreal-Garza,Anna von Wachenfeldt,Shan Wang-Gohrke,Sook-Yee Yoon,Georgia Chenevix-Trench,,,

DOI: https://doi.org/10.1002/humu.23406

2018-03-12

Human Mutation

Abstract:The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.

genetics & heredity
Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome

Christoph Engel,Aysel Ahadova,Toni T Seppälä,Stefan Aretz,Marloes Bigirwamungu-Bargeman,Hendrik Bläker,Karolin Bucksch,Reinhard Büttner,Wouter T de Vos Tot Nederveen Cappel,Volker Endris,Elke Holinski-Feder,Stefanie Holzapfel,Robert Hüneburg,Maarten A J M Jacobs,Jan J Koornstra,Alexandra M Langers,Anna Lepistö,Monika Morak,Gabriela Möslein,Päivi Peltomäki,Kirsi Pylvänäinen,Nils Rahner,Laura Renkonen-Sinisalo,Karsten Schulmann,Verena Steinke-Lange,Albrecht Stenzinger,Christian P Strassburg,Paul C van de Meeberg,Mariette van Kouwen,Monique van Leerdam,Deepak B Vangala,Juda Vecht,Marie-Louise Verhulst,Magnus von Knebel Doeberitz,Jürgen Weitz,Silke Zachariae,Markus Loeffler,Jukka-Pekka Mecklin,Matthias Kloor,Hans F Vasen,German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group,Finnish Lynch Syndrome Registry

DOI: https://doi.org/10.1053/j.gastro.2019.12.032

IF: 29.4

Gastroenterology

Abstract:Background & aims: Lynch syndrome is caused by variants in DNA mismatch repair (MMR) genes and associated with an increased risk of colorectal cancer (CRC). In patients with Lynch syndrome, CRCs can develop via different pathways. We studied associations between Lynch syndrome-associated variants in MMR genes and risks of adenoma and CRC and somatic mutations in APC and CTNNB1 in tumors in an international cohort of patients. Methods: We combined clinical and molecular data from 3 studies. We obtained clinical data from 2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, or MSH6 from Germany, the Netherlands, and Finland who received at least 2 surveillance colonoscopies and were followed for a median time of 7.8 years for development of adenomas or CRC. We performed DNA sequence analyses of 48 colorectal tumors (from 16 patients with mutations in MLH1, 29 patients with mutations in MSH2, and 3 with mutations in MSH6) for somatic mutations in APC and CTNNB1. Results: Risk of advanced adenoma in 10 years was 17.8% in patients with pathogenic variants in MSH2 vs 7.7% in MLH1 (P < .001). Higher proportions of patients with pathogenic variants in MLH1 or MSH2 developed CRC in 10 years (11.3% and 11.4%) than patients with pathogenic variants in MSH6 (4.7%) (P = .001 and P = .003 for MLH1 and MSH2 vs MSH6, respectively). Somatic mutations in APC were found in 75% of tumors from patients with pathogenic variants in MSH2 vs 11% in MLH1 (P = .015). Somatic mutations in CTNNB1 were found in 50% of tumors from patients with pathogenic variants in MLH1 vs 7% in MSH2 (P = .002). None of the 3 tumors with pathogenic variants in MSH6 had a mutation in CTNNB1, but all had mutations in APC. Conclusions: In an analysis of clinical and DNA sequence data from patients with Lynch syndrome from 3 countries, we associated pathogenic variants in MMR genes with risk of adenoma and CRC, and somatic mutations in APC and CTNNB1 in colorectal tumors. If these findings are confirmed, surveillance guidelines might be adjusted based on MMR gene variants.
Genome-wide association study of germline variants and breast cancer-specific mortality

Maria Escala-Garcia,Qi Guo,Thilo Dörk,Sander Canisius,Renske Keeman,Joe Dennis,Jonathan Beesley,Julie Lecarpentier,Manjeet K Bolla,Qin Wang,Jean Abraham,Irene L Andrulis,Hoda Anton-Culver,Volker Arndt,Paul L Auer,Matthias W Beckmann,Sabine Behrens,Javier Benitez,Marina Bermisheva,Leslie Bernstein,Carl Blomqvist,Bram Boeckx,Stig E Bojesen,Bernardo Bonanni,Anne-Lise Børresen-Dale,Hiltrud Brauch,Hermann Brenner,Adam Brentnall,Louise Brinton,Per Broberg,Ian W Brock,Sara Y Brucker,Barbara Burwinkel,Carlos Caldas,Trinidad Caldés,Daniele Campa,Federico Canzian,Angel Carracedo,Brian D Carter,Jose E Castelao,Jenny Chang-Claude,Stephen J Chanock,Georgia Chenevix-Trench,Ting-Yuan David Cheng,Suet-Feung Chin,Christine L Clarke,NBCS Collaborators,Emilie Cordina-Duverger,Fergus J Couch,David G Cox,Angela Cox,Simon S Cross,Kamila Czene,Mary B Daly,Peter Devilee,Janet A Dunn,Alison M Dunning,Lorraine Durcan,Miriam Dwek,Helena M Earl,Arif B Ekici,A Heather Eliassen,Carolina Ellberg,Christoph Engel,Mikael Eriksson,D Gareth Evans,Jonine Figueroa,Dieter Flesch-Janys,Henrik Flyger,Marike Gabrielson,Manuela Gago-Dominguez,Eva Galle,Susan M Gapstur,Montserrat García-Closas,José A García-Sáenz,Mia M Gaudet,Angela George,Vassilios Georgoulias,Graham G Giles,Gord Glendon,David E Goldgar,Anna González-Neira,Grethe I Grenaker Alnæs,Mervi Grip,Pascal Guénel,Lothar Haeberle,Eric Hahnen,Christopher A Haiman,Niclas Håkansson,Per Hall,Ute Hamann,Susan Hankinson,Elaine F Harkness,Patricia A Harrington,Steven N Hart,Jaana M Hartikainen,Alexander Hein,Peter Hillemanns,Louise Hiller,Bernd Holleczek,Antoinette Hollestelle,Maartje J Hooning,Robert N Hoover,John L Hopper,Anthony Howell,Guanmengqian Huang,Keith Humphreys,David J Hunter,Wolfgang Janni,Esther M John,Michael E Jones,Arja Jukkola-Vuorinen,Audrey Jung,Rudolf Kaaks,Maria Kabisch,Katarzyna Kaczmarek,Michael J Kerin,Sofia Khan,Elza Khusnutdinova,Johanna I Kiiski,Cari M Kitahara,Julia A Knight,Yon-Dschun Ko,Linetta B Koppert,Veli-Matti Kosma,Peter Kraft,Vessela N Kristensen,Ute Krüger,Tabea Kühl,Diether Lambrechts,Loic Le Marchand,Eunjung Lee,Flavio Lejbkowicz,Lian Li,Annika Lindblom,Sara Lindström,Martha Linet,Jolanta Lissowska,Wing-Yee Lo,Sibylle Loibl,Jan Lubiński,Michael P Lux,Robert J MacInnis,Melanie Maierthaler,Tom Maishman,Enes Makalic,Arto Mannermaa,Mehdi Manoochehri,Siranoush Manoukian,Sara Margolin,Maria Elena Martinez,Dimitrios Mavroudis,Catriona McLean,Alfons Meindl,Pooja Middha,Nicola Miller,Roger L Milne,Fernando Moreno,Anna Marie Mulligan,Claire Mulot,Rami Nassir,Susan L Neuhausen,William T Newman,Sune F Nielsen,Børge G Nordestgaard,Aaron Norman,Håkan Olsson,Nick Orr,V Shane Pankratz,Tjoung-Won Park-Simon,Jose I A Perez,Clara Pérez-Barrios,Paolo Peterlongo,Christos Petridis,Mila Pinchev,Karoliona Prajzendanc,Ross Prentice,Nadege Presneau,Darya Prokofieva,Katri Pylkäs,Brigitte Rack,Paolo Radice,Dhanya Ramachandran,Gadi Rennert,Hedy S Rennert,Valerie Rhenius,Atocha Romero,Rebecca Roylance,Emmanouil Saloustros,Elinor J Sawyer,Daniel F Schmidt,Rita K Schmutzler,Andreas Schneeweiss,Minouk J Schoemaker,Fredrick Schumacher,Lukas Schwentner,Rodney J Scott,Christopher Scott,Caroline Seynaeve,Mitul Shah,Jacques Simard,Ann Smeets,Christof Sohn,Melissa C Southey,Anthony J Swerdlow,Aline Talhouk,Rulla M Tamimi,William J Tapper,Manuel R Teixeira,Maria Tengström,Mary Beth Terry,Kathrin Thöne,Rob A E M Tollenaar,Ian Tomlinson,Diana Torres,Thérèse Truong,Constance Turman,Clare Turnbull,Hans-Ulrich Ulmer,Michael Untch,Celine Vachon,Christi J van Asperen,Ans M W van den Ouweland,Elke M van Veen,Camilla Wendt,Alice S Whittemore,Walter Willett,Robert Winqvist,Alicja Wolk,Xiaohong R Yang,Yan Zhang,Douglas F Easton,Peter A Fasching,Heli Nevanlinna,Diana M Eccles,Paul D P Pharoah,Marjanka K Schmidt

DOI: https://doi.org/10.1038/s41416-019-0393-x

Abstract:Background: We examined the associations between germline variants and breast cancer mortality using a large meta-analysis of women of European ancestry. Methods: Meta-analyses included summary estimates based on Cox models of twelve datasets using ~10.4 million variants for 96,661 women with breast cancer and 7697 events (breast cancer-specific deaths). Oestrogen receptor (ER)-specific analyses were based on 64,171 ER-positive (4116) and 16,172 ER-negative (2125) patients. We evaluated the probability of a signal to be a true positive using the Bayesian false discovery probability (BFDP). Results: We did not find any variant associated with breast cancer-specific mortality at P < 5 × 10-8. For ER-positive disease, the most significantly associated variant was chr7:rs4717568 (BFDP = 7%, P = 1.28 × 10-7, hazard ratio [HR] = 0.88, 95% confidence interval [CI] = 0.84-0.92); the closest gene is AUTS2. For ER-negative disease, the most significant variant was chr7:rs67918676 (BFDP = 11%, P = 1.38 × 10-7, HR = 1.27, 95% CI = 1.16-1.39); located within a long intergenic non-coding RNA gene (AC004009.3), close to the HOXA gene cluster. Conclusions: We uncovered germline variants on chromosome 7 at BFDP < 15% close to genes for which there is biological evidence related to breast cancer outcome. However, the paucity of variants associated with mortality at genome-wide significance underpins the challenge in providing genetic-based individualised prognostic information for breast cancer patients.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Timothy R Rebbeck,Nandita Mitra,Fei Wan,Olga M Sinilnikova,Sue Healey,Lesley McGuffog,Sylvie Mazoyer,Georgia Chenevix-Trench,Douglas F Easton,Antonis C Antoniou,Katherine L Nathanson,CIMBA Consortium,Yael Laitman,Anya Kushnir,Shani Paluch-Shimon,Raanan Berger,Jamal Zidan,Eitan Friedman,Hans Ehrencrona,Marie Stenmark-Askmalm,Zakaria Einbeigi,Niklas Loman,Katja Harbst,Johanna Rantala,Beatrice Melin,Dezheng Huo,Olufunmilayo I Olopade,Joyce Seldon,Patricia A Ganz,Robert L Nussbaum,Salina B Chan,Kunle Odunsi,Simon A Gayther,Susan M Domchek,Banu K Arun,Karen H Lu,Gillian Mitchell,Beth Y Karlan,Christine Walsh,Jenny Lester,Andrew K Godwin,Harsh Pathak,Eric Ross,Mary B Daly,Alice S Whittemore,Esther M John,Alexander Miron,Mary Beth Terry,Wendy K Chung,David E Goldgar,Saundra S Buys,Ramunas Janavicius,Laima Tihomirova,Nadine Tung,Cecilia M Dorfling,Elizabeth J van Rensburg,Linda Steele,Susan L Neuhausen,Yuan Chun Ding,Bent Ejlertsen,Anne-Marie Gerdes,Thomas v O Hansen,Teresa Ramón y Cajal,Ana Osorio,Javier Benitez,Javier Godino,Maria-Isabel Tejada,Mercedes Duran,Jeffrey N Weitzel,Kristie A Bobolis,Sharon R Sand,Annette Fontaine,Antonella Savarese,Barbara Pasini,Bernard Peissel,Bernardo Bonanni,Daniela Zaffaroni,Francesca Vignolo-Lutati,Giulietta Scuvera,Giuseppe Giannini,Loris Bernard,Maurizio Genuardi,Paolo Radice,Riccardo Dolcetti,Siranoush Manoukian,Valeria Pensotti,Viviana Gismondi,Drakoulis Yannoukakos,Florentia Fostira,Judy Garber,Diana Torres,Muhammad Usman Rashid,Ute Hamann,Susan Peock,Debra Frost,Radka Platte,D Gareth Evans,Rosalind Eeles,Rosemarie Davidson,Diana Eccles,Trevor Cole,Jackie Cook,Carole Brewer,Shirley Hodgson,Patrick J Morrison,Lisa Walker,Mary E Porteous,M John Kennedy,Louise Izatt,Julian Adlard,Alan Donaldson,Steve Ellis,Priyanka Sharma,Rita Katharina Schmutzler,Barbara Wappenschmidt,Alexandra Becker,Kerstin Rhiem,Eric Hahnen,Christoph Engel,Alfons Meindl,Stefanie Engert,Nina Ditsch,Norbert Arnold,Hans Jörg Plendl,Christoph Mundhenke,Dieter Niederacher,Markus Fleisch,Christian Sutter,C R Bartram,Nicola Dikow,Shan Wang-Gohrke,Dorothea Gadzicki,Doris Steinemann,Karin Kast,Marit Beer,Raymonda Varon-Mateeva,Andrea Gehrig,Bernhard H Weber,Dominique Stoppa-Lyonnet,Claude Houdayer,Muriel Belotti,Marion Gauthier-Villars,Francesca Damiola,Nadia Boutry-Kryza,Christine Lasset,Hagay Sobol,Jean-Philippe Peyrat,Danièle Muller,Jean-Pierre Fricker,Marie-Agnès Collonge-Rame,Isabelle Mortemousque,Catherine Nogues,Etienne Rouleau,Claudine Isaacs,Anne De Paepe,Bruce Poppe,Kathleen Claes,Kim De Leeneer,Marion Piedmonte,Gustavo Rodriguez,Katie Wakely,John Boggess,Stephanie V Blank,Jack Basil,Masoud Azodi,Kelly-Anne Phillips,Trinidad Caldes,Miguel de la Hoya,Atocha Romero,Heli Nevanlinna,Kristiina Aittomäki,Annemarie H van der Hout,Frans B L Hogervorst,Senno Verhoef,J Margriet Collée,Caroline Seynaeve,Jan C Oosterwijk,Johannes J P Gille,Juul T Wijnen,Encarna B Gómez Garcia,Carolien M Kets,Margreet G E M Ausems,Cora M Aalfs,Peter Devilee,Arjen R Mensenkamp,Ava Kwong,Edith Olah,Janos Papp,Orland Diez,Conxi Lazaro,Esther Darder,Ignacio Blanco,Mónica Salinas,Anna Jakubowska,Jan Lubinski,Jacek Gronwald,Katarzyna Jaworska-Bieniek,Katarzyna Durda,Grzegorz Sukiennicki,Tomasz Huzarski,Tomasz Byrski,Cezary Cybulski,Aleksandra Toloczko-Grabarek,Elżbieta Złowocka-Perłowska,Janusz Menkiszak,Adalgeir Arason,Rosa B Barkardottir,Jacques Simard,Rachel Laframboise,Marco Montagna,Simona Agata,Elisa Alducci,Ana Peixoto,Manuel R Teixeira,Amanda B Spurdle,Min Hyuk Lee,Sue K Park,Sung-Won Kim,Tara M Friebel,Fergus J Couch,Noralane M Lindor,Vernon S Pankratz,Lucia Guidugli,Xianshu Wang,Marc Tischkowitz,Lenka Foretova,Joseph Vijai,Kenneth Offit,Mark Robson,Rohini Rau-Murthy,Noah Kauff,Anneliese Fink-Retter,Christian F Singer,Christine Rappaport,Daphne Gschwantler-Kaulich,Georg Pfeiler,Muy-Kheng Tea,Andreas Berger,Mark H Greene,Phuong L Mai,Evgeny N Imyanitov,Amanda Ewart Toland,Leigha Senter,Anders Bojesen,Inge Sokilde Pedersen,Anne-Bine Skytte,Lone Sunde,Mads Thomassen,Sanne Traasdahl Moeller,Torben A Kruse,Uffe Birk Jensen,Maria Adelaide Caligo,Paolo Aretini,Soo-Hwang Teo,Christina G Selkirk,Peter J Hulick,Irene Andrulis

DOI: https://doi.org/10.1001/jama.2014.5985

IF: 11.816

2015-04-07

JAMA

Abstract:Importance: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. Objective: To identify mutation-specific cancer risks for carriers of BRCA1/2. Design, setting, and participants: Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. Exposures: Mutations of BRCA1 or BRCA2. Main outcomes and measures: Breast and ovarian cancer risks. Results: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 × 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 × 10(-9)). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 × 10(-17)). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69-3.16; P = .00002). We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95% CI, 0.44-0.60; P = 6 × 10(-17)). The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41-0.80; P = .001). Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers. Conclusions and relevance: Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations.
The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

Ying Yuan,Lizhen Zhu,Dong Xu,Ju Haixing,Yan Sun,Pei-Rong Ding

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e13518

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e13518 Background: Mismatch repair deficiency (dMMR) assessed by microsatellite instability (MSI) or immunohistochemistry (IHC) is a feature of Lynch syndrome, a major hereditary colorectal cancer (CRC). Chinese Lynch syndrome criteria was proposed based on the decreasing family numbers: In a pedigree, it should have at least 2 CRCs, and at least 2 of them are first-degree relatives of each other. Besides, any one of following criteria should be met: 1) at least 1 CRC should have multiple primary synchronous/metachronous colorectal carcinoma/adenoma; 2) at least 1 CRC should be diagnosed before 50 years old; 3) in the pedigree, at least 1 should be diagnosed with other Lynch syndrome-related cancer (i.e. gastric, endometrial, small bowel, ureter, or renal-pelvic, ovarian and hepatobiliary cancers). The purpose of this multi-center study is to derive prevalence of germline mutations in Chinese dMMR CRC, especially taking different screen criteria for Lynch syndrome into consideration. Methods: ColonCore panel is designed for simultaneous detection of MSI and mutations in 41 CRC-related genes by next generation sequencing (NGS). Primary CRC patients with loss of expression of any one of four MMR proteins (MLH1, MSH2, MSH6 and PMS2) in IHC were recruited. DNA was extracted from paired tumor-normal tissue for MSI detection and germline and somatic sequencing by ColonCore panel. Results: A total of 205 patients were enrolled. The MSI detection by NGS achieved 94% concordance with IHC. We revealed 32% patients had pathogenic germline mutations, with 14%, 7%, 5%, 2% and 3% patients carrying MLH1, MSH2, MSH6, PMS2 and other gene mutations respectively. Among all 205 patients, 7%, 12% and 42% patients met Amsterdam II criteria, Chinese Lynch syndrome criteria and revised Bethesda Guidelines respectively. Besides, 100%, 80% and 53% patients had pathogenic mutations and 27%, 24% and 15% patients with pathogenic germline mutations were missed according to Amsterdam II criteria, Chinese Lynch syndrome criteria and revised Bethesda Guidelines respectively. Conclusions: We found that 32% IHC dMMR CRCs have pathogenic germline mutations, and Chinese Lynch syndrome criteria is an effective screening criteria.
No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer.

Antoinette Hollestelle,Frederieke H van der Baan,Andrew Berchuck,Sharon E Johnatty,Katja K Aben,Bjarni A Agnarsson,Kristiina Aittomäki,Elisa Alducci,Irene L Andrulis,Hoda Anton-Culver,Natalia N Antonenkova,Antonis C Antoniou,Carmel Apicella,Volker Arndt,Norbert Arnold,Banu K Arun,Brita Arver,Alan Ashworth,Australian Ovarian Cancer Study Group,Laura Baglietto,Rosemary Balleine,Elisa V Bandera,Daniel Barrowdale,Yukie T Bean,Lars Beckmann,Matthias W Beckmann,Javier Benitez,Andreas Berger,Raanan Berger,Benoit Beuselinck,Maria Bisogna,Line Bjorge,Carl Blomqvist,Natalia V Bogdanova,Anders Bojesen,Stig E Bojesen,Manjeet K Bolla,Bernardo Bonanni,Judith S Brand,Hiltrud Brauch,Breast Cancer Family Register,Hermann Brenner,Louise Brinton,Angela Brooks-Wilson,Fiona Bruinsma,Joan Brunet,Thomas Brüning,Agnieszka Budzilowska,Clareann H Bunker,Barbara Burwinkel,Ralf Butzow,Saundra S Buys,Maria A Caligo,Ian Campbell,Jonathan Carter,Jenny Chang-Claude,Stephen J Chanock,Kathleen B M Claes,J Margriet Collée,Linda S Cook,Fergus J Couch,Angela Cox,Daniel Cramer,Simon S Cross,Julie M Cunningham,Cezary Cybulski,Kamila Czene,Francesca Damiola,Agnieszka Dansonka-Mieszkowska,Hatef Darabi,Miguel de la Hoya,Anna deFazio,Joseph Dennis,Peter Devilee,Ed M Dicks,Orland Diez,Jennifer A Doherty,Susan M Domchek,Cecilia M Dorfling,Thilo Dörk,Isabel Dos Santos Silva,Andreas du Bois,Martine Dumont,Alison M Dunning,Mercedes Duran,Douglas F Easton,Diana Eccles,Robert P Edwards,Hans Ehrencrona,Bent Ejlertsen,Arif B Ekici,Steve D Ellis,EMBRACE,Christoph Engel,Mikael Eriksson,Peter A Fasching,Lidia Feliubadalo,Jonine Figueroa,Dieter Flesch-Janys,Olivia Fletcher,Annette Fontaine,Stefano Fortuzzi,Florentia Fostira,Brooke L Fridley,Tara Friebel,Eitan Friedman,Grace Friel,Debra Frost,Judy Garber,Montserrat García-Closas,Simon A Gayther,GEMO Study Collaborators,GENICA Network,Aleksandra Gentry-Maharaj,Anne-Marie Gerdes,Graham G Giles,Rosalind Glasspool,Gord Glendon,Andrew K Godwin,Marc T Goodman,Martin Gore,Mark H Greene,Mervi Grip,Jacek Gronwald,Daphne Gschwantler Kaulich,Pascal Guénel,Starr R Guzman,Lothar Haeberle,Christopher A Haiman,Per Hall,Sandra L Halverson,Ute Hamann,Thomas V O Hansen,Philipp Harter,Jaana M Hartikainen,Sue Healey,HEBON,Alexander Hein,Florian Heitz,Brian E Henderson,Josef Herzog,Michelle A T Hildebrandt,Claus K Høgdall,Estrid Høgdall,Frans B L Hogervorst,John L Hopper,Keith Humphreys,Tomasz Huzarski,Evgeny N Imyanitov,Claudine Isaacs,Anna Jakubowska,Ramunas Janavicius,Katarzyna Jaworska,Allan Jensen,Uffe Birk Jensen,Nichola Johnson,Arja Jukkola-Vuorinen,Maria Kabisch,Beth Y Karlan,Vesa Kataja,Noah Kauff,KConFab Investigators,Linda E Kelemen,Michael J Kerin,Lambertus A Kiemeney,Susanne K Kjaer,Julia A Knight,Jacoba P Knol-Bout,Irene Konstantopoulou,Veli-Matti Kosma,Camilla Krakstad,Vessela Kristensen,Karoline B Kuchenbaecker,Jolanta Kupryjanczyk,Yael Laitman,Diether Lambrechts,Sandrina Lambrechts,Melissa C Larson,Adriana Lasa,Pierre Laurent-Puig,Conxi Lazaro,Nhu D Le,Loic Le Marchand,Arto Leminen,Jenny Lester,Douglas A Levine,Jingmei Li,Dong Liang,Annika Lindblom,Noralane Lindor,Jolanta Lissowska,Jirong Long,Karen H Lu,Jan Lubinski,Lene Lundvall,Galina Lurie,Phuong L Mai,Arto Mannermaa,Sara Margolin,Frederique Mariette,Frederik Marme,John W M Martens,Leon F A G Massuger,Christine Maugard,Sylvie Mazoyer,Lesley McGuffog,Valerie McGuire,Catriona McLean,Iain McNeish,Alfons Meindl,Florence Menegaux,Primitiva Menéndez,Janusz Menkiszak,Usha Menon,Arjen R Mensenkamp,Nicola Miller,Roger L Milne,Francesmary Modugno,Marco Montagna,Kirsten B Moysich,Heiko Müller,Anna Marie Mulligan,Taru A Muranen,Steven A Narod,Katherine L Nathanson,Roberta B Ness,Susan L Neuhausen,Heli Nevanlinna,Patrick Neven,Finn C Nielsen,Sune F Nielsen,Børge G Nordestgaard,Robert L Nussbaum,Kunle Odunsi,Kenneth Offit,Edith Olah,Olufunmilayo I Olopade,Janet E Olson,Sara H Olson,Jan C Oosterwijk,Irene Orlow,Nick Orr,Sandra Orsulic,Ana Osorio,Laura Ottini,James Paul,Celeste L Pearce,Inge Sokilde Pedersen,Bernard Peissel,Tanja Pejovic,Liisa M Pelttari,Jo Perkins,Jenny Permuth-Wey,Paolo Peterlongo,Julian Peto,Catherine M Phelan,Kelly-Anne Phillips,Marion Piedmonte,Malcolm C Pike,Radka Platte,Joanna Plisiecka-Halasa,Elizabeth M Poole,Bruce Poppe,Katri Pylkäs,Paolo Radice,Susan J Ramus,Timothy R Rebbeck,Malcolm W R Reed,Gad Rennert,Harvey A Risch,Mark Robson,Gustavo C Rodriguez,Atocha Romero,Mary Anne Rossing,Joseph H Rothstein,Anja Rudolph,Ingo Runnebaum,Ritu Salani,Helga B Salvesen,Elinor J Sawyer,Joellen M Schildkraut,Marjanka K Schmidt,Rita K Schmutzler,Andreas Schneeweiss,Minouk J Schoemaker,Michael G Schrauder,Fredrick Schumacher,Ira Schwaab,Giulietta Scuvera,Thomas A Sellers,Gianluca Severi,Caroline M Seynaeve,Mitul Shah,Martha Shrubsole,Nadeem Siddiqui,Weiva Sieh,Jacques Simard,Christian F Singer,Olga M Sinilnikova,Dominiek Smeets,Christof Sohn,Maria Soller,Honglin Song,Penny Soucy,Melissa C Southey,Christa Stegmaier,Dominique Stoppa-Lyonnet,Lara Sucheston,SWE-BRCA,Anthony Swerdlow,Ingvild L Tangen,Muy-Kheng Tea,Manuel R Teixeira,Kathryn L Terry,Mary Beth Terry,Mads Thomassen,Pamela J Thompson,Laima Tihomirova,Marc Tischkowitz,Amanda Ewart Toland,Rob A E M Tollenaar,Ian Tomlinson,Diana Torres,Thérèse Truong,Helen Tsimiklis,Nadine Tung,Shelley S Tworoger,Jonathan P Tyrer,Celine M Vachon,Laura J Van 't Veer,Anne M van Altena,C J Van Asperen,David van den Berg,Ans M W van den Ouweland,Helena C van Doorn,Els Van Nieuwenhuysen,Elizabeth J van Rensburg,Ignace Vergote,Senno Verhoef,Robert A Vierkant,Joseph Vijai,Allison F Vitonis,Anna von Wachenfeldt,Christine Walsh,Qin Wang,Shan Wang-Gohrke,Barbara Wappenschmidt,Maren Weischer,Jeffrey N Weitzel,Caroline Weltens,Nicolas Wentzensen,Alice S Whittemore,Lynne R Wilkens,Robert Winqvist,Anna H Wu,Xifeng Wu,Hannah P Yang,Daniela Zaffaroni,M Pilar Zamora,Wei Zheng,Argyrios Ziogas,Georgia Chenevix-Trench,Paul D P Pharoah,Matti A Rookus,Maartje J Hooning,Ellen L Goode

DOI: https://doi.org/10.1016/j.ygyno.2015.04.034

IF: 5.304

2015-01-01

Gynecologic Oncology

Abstract:OBJECTIVE:Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.METHODS:Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).RESULTS:We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.CONCLUSIONS:rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Thomas U Ahearn,Haoyu Zhang,Kyriaki Michailidou,Roger L Milne,Manjeet K Bolla,Joe Dennis,Alison M Dunning,Michael Lush,Qin Wang,Irene L Andrulis,Hoda Anton-Culver,Volker Arndt,Kristan J Aronson,Paul L Auer,Annelie Augustinsson,Adinda Baten,Heiko Becher,Sabine Behrens,Javier Benitez,Marina Bermisheva,Carl Blomqvist,Stig E Bojesen,Bernardo Bonanni,Anne-Lise Børresen-Dale,Hiltrud Brauch,Hermann Brenner,Angela Brooks-Wilson,Thomas Brüning,Barbara Burwinkel,Saundra S Buys,Federico Canzian,Jose E Castelao,Jenny Chang-Claude,Stephen J Chanock,Georgia Chenevix-Trench,Christine L Clarke,NBCS Collaborators,J Margriet Collée,Angela Cox,Simon S Cross,Kamila Czene,Mary B Daly,Peter Devilee,Thilo Dörk,Miriam Dwek,Diana M Eccles,D Gareth Evans,Peter A Fasching,Jonine Figueroa,Giuseppe Floris,Manuela Gago-Dominguez,Susan M Gapstur,José A García-Sáenz,Mia M Gaudet,Graham G Giles,Mark S Goldberg,Anna González-Neira,Grethe I Grenaker Alnæs,Mervi Grip,Pascal Guénel,Christopher A Haiman,Per Hall,Ute Hamann,Elaine F Harkness,Bernadette A M Heemskerk-Gerritsen,Bernd Holleczek,Antoinette Hollestelle,Maartje J Hooning,Robert N Hoover,John L Hopper,Anthony Howell,ABCTB Investigators,kConFab/AOCS Investigators,Milena Jakimovska,Anna Jakubowska,Esther M John,Michael E Jones,Audrey Jung,Rudolf Kaaks,Saila Kauppila,Renske Keeman,Elza Khusnutdinova,Cari M Kitahara,Yon-Dschun Ko,Stella Koutros,Vessela N Kristensen,Ute Krüger,Katerina Kubelka-Sabit,Allison W Kurian,Kyriacos Kyriacou,Diether Lambrechts,Derrick G Lee,Annika Lindblom,Martha Linet,Jolanta Lissowska,Ana Llaneza,Wing-Yee Lo,Robert J MacInnis,Arto Mannermaa,Mehdi Manoochehri,Sara Margolin,Maria Elena Martinez,Catriona McLean,Alfons Meindl,Usha Menon,Heli Nevanlinna,William G Newman,Jesse Nodora,Kenneth Offit,Håkan Olsson,Nick Orr,Tjoung-Won Park-Simon,Alpa V Patel,Julian Peto,Guillermo Pita,Dijana Plaseska-Karanfilska,Ross Prentice,Kevin Punie,Katri Pylkäs,Paolo Radice,Gad Rennert,Atocha Romero,Thomas Rüdiger,Emmanouil Saloustros,Sarah Sampson,Dale P Sandler,Elinor J Sawyer,Rita K Schmutzler,Minouk J Schoemaker,Ben Schöttker,Mark E Sherman,Xiao-Ou Shu,Snezhana Smichkoska,Melissa C Southey,John J Spinelli,Anthony J Swerdlow,Rulla M Tamimi,William J Tapper,Jack A Taylor,Lauren R Teras,Mary Beth Terry,Diana Torres,Melissa A Troester,Celine M Vachon,Carolien H M van Deurzen,Elke M van Veen,Philippe Wagner,Clarice R Weinberg,Camilla Wendt,Jelle Wesseling,Robert Winqvist,Alicja Wolk,Xiaohong R Yang,Wei Zheng,Fergus J Couch,Jacques Simard,Peter Kraft,Douglas F Easton,Paul D P Pharoah,Marjanka K Schmidt,Montserrat García-Closas,Nilanjan Chatterjee,Kristine K Sahlberg,Lars Ottestad,Rolf Kåresen,Ellen Schlichting,Marit Muri Holmen,Toril Sauer,Vilde Haakensen,Olav Engebråten,Bjørn Naume,Alexander Fosså,Cecile E Kiserud,Kristin V Reinertsen,Åslaug Helland,Margit Riis,Jürgen Geisler,Christine Clarke,Rosemary Balleine,Robert Baxter,Stephen Braye,Jane Carpenter,Jane Dahlstrom,John Forbes,CSoon Lee,Deborah Marsh,Adrienne Morey,Nirmala Pathmanathan,Rodney Scott,Peter Simpson,Allan Spigelman,Nicholas Wilcken,Desmond Yip,Nikolajs Zeps,Stephen Fox,Ian Campbell,David Bowtell,Amanda Spurdle,Penny Webb,Anna de Fazio,Margaret Tassell,Judy Kirk,Geoff Lindeman,Melanie Price,Melissa Southey,Roger Milne,Sid Deb

DOI: https://doi.org/10.1186/s13058-021-01484-x

2022-01-04

Abstract:Background: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear. Methods: Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes. Results: Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at p < 0.05 with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions. Conclusion: This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study

Ayse Bahar Ercan,Melyssa Aronson,Nicholas R Fernandez,Yuan Chang,Adrian Levine,Zhihui Amy Liu,Logine Negm,Melissa Edwards,Vanessa Bianchi,Lucie Stengs,Jiil Chung,Abeer Al-Battashi,Agnes Reschke,Alex Lion,Alia Ahmad,Alvaro Lassaletta,Alyssa T Reddy,Amir F Al-Darraji,Amish C Shah,An Van Damme,Anne Bendel,Aqeela Rashid,Ashley S Margol,Bethany L Kelly,Bojana Pencheva,Brandie Heald,Brianna Lemieux-Anglin,Bruce Crooks,Carl Koschmann,Catherine Gilpin,Christopher C Porter,David Gass,David Samuel,David S Ziegler,Deborah T Blumenthal,Dennis John Kuo,Dima Hamideh,Donald Basel,Dong-Anh Khuong-Quang,Duncan Stearns,Enrico Opocher,Fernando Carceller,Hagit Baris Feldman,Helen Toledano,Ira Winer,Isabelle Scheers,Ivana Fedorakova,Jack M Su,Jaime Vengoechea,Jaroslav Sterba,Jeffrey Knipstein,Jordan R Hansford,Julieta Rita Gonzales-Santos,Kanika Bhatia,Kevin J Bielamowicz,Khurram Minhas,Kim E Nichols,Kristina A Cole,Lynette Penney,Magnus Aasved Hjort,Magnus Sabel,Maria Joao Gil-da-Costa,Matthew J Murray,Matthew Miller,Maude L Blundell,Maura Massimino,Maysa Al-Hussaini,Mazin F Al-Jadiry,Melanie A Comito,Michael Osborn,Michael P Link,Michal Zapotocky,Mithra Ghalibafian,Najma Shaheen,Naureen Mushtaq,Nicolas Waespe,Nobuko Hijiya,Noemi Fuentes-Bolanos,Olfat Ahmad,Omar Chamdine,Paromita Roy,Pavel N Pichurin,Per Nyman,Rachel Pearlman,Rebecca C Auer,Reghu K Sukumaran,Rejin Kebudi,Rina Dvir,Robert Raphael,Ronit Elhasid,Rose B McGee,Rose Chami,Ryan Noss,Ryuma Tanaka,Salmo Raskin,Santanu Sen,Scott Lindhorst,Sebastien Perreault,Shani Caspi,Shazia Riaz,Shlomi Constantini,Sophie Albert,Stanley Chaleff,Stefan Bielack,Stefano Chiaravalli,Stuart Louis Cramer,Sumita Roy,Suzanne Cahn,Suzanne Penna,Syed Ahmer Hamid,Tariq Ghafoor,Uzma Imam,Valerie Larouche,Vanan Magimairajan Issai,William D Foulkes,Yi Yen Lee,Paul C Nathan,Yosef E Maruvka,Mary-Louise C Greer,Carol Durno,Adam Shlien,Birgit Ertl-Wagner,Anita Villani,David Malkin,Cynthia Hawkins,Eric Bouffet,Anirban Das,Uri Tabori

DOI: https://doi.org/10.1016/S1470-2045(24)00026-3

Abstract:Background: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes, we aimed to describe the clinical spectrum, cancer biology, and impact of genetics on patient survival in CMMRD. Methods: In this cohort study, we collected cross-sectional and longitudinal data on all patients with CMMRD, with no age limits, registered with the International Replication Repair Deficiency Consortium (IRRDC) across more than 50 countries. Clinical data were extracted from the IRRDC database, medical records, and physician-completed case record forms. The primary objective was to describe the clinical features, cancer spectrum, and biology of the condition. Secondary objectives included estimations of cancer incidence and of the impact of the specific mismatch-repair gene and genotype on cancer onset and survival, including after cancer surveillance and immunotherapy interventions. Findings: We analysed data from 201 patients (103 males, 98 females) enrolled between June 5, 2007 and Sept 9, 2022. Median age at diagnosis of CMMRD or a related cancer was 8·9 years (IQR 5·9-12·6), and median follow-up from diagnosis was 7·2 years (3·6-14·8). Endogamy among minorities and closed communities contributed to high homozygosity within countries with low consanguinity. Frequent dermatological manifestations (117 [93%] of 126 patients with complete data) led to a clinical overlap with neurofibromatosis type 1 (35 [28%] of 126). 339 cancers were reported in 194 (97%) of 201 patients. The cumulative cancer incidence by age 18 years was 90% (95% CI 80-99). Median time between cancer diagnoses for patients with more than one cancer was 1·9 years (IQR 0·8-3·9). Neoplasms developed in 15 organs and included early-onset adult cancers. CNS tumours were the most frequent (173 [51%] cancers), followed by gastrointestinal (75 [22%]), haematological (61 [18%]), and other cancer types (30 [9%]). Patients with CNS tumours had the poorest overall survival rates (39% [95% CI 30-52] at 10 years from diagnosis; log-rank p<0·0001 across four cancer types), followed by those with haematological cancers (67% [55-82]), gastrointestinal cancers (89% [81-97]), and other solid tumours (96% [88-100]). All cancers showed high mutation and microsatellite indel burdens, and pathognomonic mutational signatures. MLH1 or MSH2 variants caused earlier cancer onset than PMS2 or MSH6 variants, and inferior survival (overall survival at age 15 years 63% [95% CI 55-73] for PMS2, 49% [35-68] for MSH6, 19% [6-66] for MLH1, and 0% for MSH2; p<0·0001). Frameshift or truncating variants within the same gene caused earlier cancers and inferior outcomes compared with missense variants (p<0·0001). The greater deleterious effects of MLH1 and MSH2 variants as compared with PMS2 and MSH6 variants persisted despite overall improvements in survival after surveillance or immune checkpoint inhibitor interventions. Interpretation: The very high cancer burden and unique genomic landscape of CMMRD highlight the benefit of comprehensive assays in timely diagnosis and precision approaches toward surveillance and immunotherapy. These data will guide the clinical management of children and patients who survive into adulthood with CMMRD. Funding: The Canadian Institutes for Health Research, Stand Up to Cancer, Children's Oncology Group National Cancer Institute Community Oncology Research Program, Canadian Cancer Society, Brain Canada, The V Foundation for Cancer Research, BioCanRx, Harry and Agnieszka Hall, Meagan's Walk, BRAINchild Canada, The LivWise Foundation, St Baldrick Foundation, Hold'em for Life, and Garron Family Cancer Center.
Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes - an EHTG, PLSD position statement

Pal Møller,Toni T. Seppälä,Aysel Ahadova,Emma J. Crosbie,Elke Holinski-Feder,Rodney Scott,Saskia Haupt,Gabriela Möslein,Ingrid Winship,Sanne W. Bajwa-ten Broeke,Kelly E. Kohut,Neil Ryan,Peter Bauerfeind,Laura E. Thomas,D. Gareth Evans,Stefan Aretz,Rolf H. Sijmons,Elizabeth Half,Karl Heinimann,Karoline Horisberger,Kevin Monahan,Christoph Engel,Giulia Martina Cavestro,Robert Fruscio,Naim Abu-Freha,Levi Zohar,Luigi Laghi,Lucio Bertario,Bernardo Bonanni,Maria Grazia Tibiletti,Leonardo S. Lino-Silva,Carlos Vaccaro,Adriana Della Valle,Benedito Mauro Rossi,Leandro Apolinário da Silva,Ivana Lucia de Oliveira Nascimento,Norma Teresa Rossi,Tadeusz Dębniak,Jukka-Pekka Mecklin,Inge Bernstein,Annika Lindblom,Lone Sunde,Sigve Nakken,Vincent Heuveline,John Burn,Eivind Hovig,Matthias Kloor,Julian R. Sampson,Mev Dominguez-Valentin,On behalf of the Prospective Lynch Syndrome Database (www.plsd.eu) and The European Hereditary Tumour Group (www.ehtg.org)

DOI: https://doi.org/10.1186/s13053-023-00263-3

2023-10-13

Hereditary Cancer in Clinical Practice

Abstract:The recognition of dominantly inherited micro-satellite instable (MSI) cancers caused by pathogenic variants in one of the four mismatch repair ( MMR ) genes MSH2, MLH1, MSH6 and PMS2 has modified our understanding of carcinogenesis. Inherited loss of function variants in each of these MMR genes cause four dominantly inherited cancer syndromes with different penetrance and expressivities: the four Lynch syndromes. No person has an "average sex "or a pathogenic variant in an "average Lynch syndrome gene" and results that are not stratified by gene and sex will be valid for no one. Carcinogenesis may be a linear process from increased cellular division to localized cancer to metastasis. In addition, in the Lynch syndromes (LS) we now recognize a dynamic balance between two stochastic processes: MSI producing abnormal cells, and the host's adaptive immune system's ability to remove them. The latter may explain why colonoscopy surveillance does not reduce the incidence of colorectal cancer in LS, while it may improve the prognosis. Most early onset colon, endometrial and ovarian cancers in LS are now cured and most cancer related deaths are after subsequent cancers in other organs. Aspirin reduces the incidence of colorectal and other cancers in LS. Immunotherapy increases the host immune system's capability to destroy MSI cancers. Colonoscopy surveillance, aspirin prevention and immunotherapy represent major steps forward in personalized precision medicine to prevent and cure inherited MSI cancer.

oncology
Cancer Risks for PMS2-Associated Lynch Syndrome.

Sanne W. ten Broeke,Heleen M. van der Klift,Carli M.J. Tops,Stefan Aretz,Inge Bernstein,Daniel D. Buchanan,Albert de la Chapelle,Gabriel Capella,Mark Clendenning,Christoph Engel,Steven Gallinger,Encarna Gomez Garcia,Jane C. Figueiredo,Robert Haile,Heather L. Hampel,Liselotte van Hest,John L. Hopper,Nicoline Hoogerbrugge,Magnus von Knebel Doeberitz,Loic Le Marchand,Tom G.W. Letteboer,Mark A. Jenkins,Annika Lindblom,Noralane M. Lindor,Arjen R. Mensenkamp,Pål Møller,Polly A. Newcomb,Theo A.M. van Os,Rachel Pearlman,Marta Pineda,Nils Rahner,Egbert J.W. Redeker,Maran J.W. Olderode-Berends,Christophe Rosty,Hans K. Schackert,Rodney Scott,Leigha Senter,Liesbeth Spruijt,Verena Steinke-Lange,Manon Suerink,Stephen Thibodeau,Yvonne J. Vos,Anja Wagner,Ingrid Winship,Frederik J. Hes,Hans F.A. Vasen,Juul T. Wijnen,Maartje Nielsen,Aung Ko Win,Daniel D Buchanan,Hans K Schackert,Carli M J Tops,Yvonne J Vos,Theo A M van Os,Noralane M Lindor,Heleen M van der Klift,Mark A Jenkins,Maran J W Olderode-Berends,Arjen R Mensenkamp,Heather L Hampel,Juul T Wijnen,Hans F A Vasen,Polly A Newcomb,Egbert J W Redeker,Tom G W Letteboer,Jane C Figueiredo,John L Hopper,Frederik J Hes,Sanne W Ten Broeke

DOI: https://doi.org/10.1200/JCO.2018.78.4777

IF: 45.3

2019-10-03

Journal of Clinical Oncology

Abstract:Purpose Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 variants. Methods A modified segregation analysis was conducted that incorporated both genotyped and nongenotyped relatives, with conditioning for ascertainment to estimates corrected for bias. Hazard ratios (HRs) and corresponding 95% CIs were estimated for each cancer site for mutation carriers compared with the general population, followed by estimation of penetrance. Results In total, 284 families consisting of 4,878 first- and second-degree family members were included in the analysis. PMS2 mutation carriers were at increased risk for colorectal cancer (cumulative risk to age 80 years of 13% [95% CI, 7.9% to 22%] for males and 12% [95% CI, 6.7% to 21%] for females) and endometrial cancer (13% [95% CI, 7.0%-24%]), compared with the general population (6.6%, 4.7%, and 2.4%, respectively). There was no clear evidence of an increased risk of ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. Conclusion Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. This finding justifies that PMS2-specific screening protocols could be restricted to colonoscopies. The role of risk-reducing hysterectomy and bilateral salpingo-oophorectomy for PMS2 mutation carriers needs further discussion.

oncology
Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

Ceres Fernandez-Rozadilla,Maria Timofeeva,Zhishan Chen,Philip Law,Minta Thomas,Stephanie Schmit,Virginia Díez-Obrero,Li Hsu,Juan Fernandez-Tajes,Claire Palles,Kitty Sherwood,Sarah Briggs,Victoria Svinti,Kevin Donnelly,Susan Farrington,James Blackmur,Peter Vaughan-Shaw,Xiao-ou Shu,Jirong Long,Qiuyin Cai,Xingyi Guo,Yingchang Lu,Peter Broderick,James Studd,Jeroen Huyghe,Tabitha Harrison,David Conti,Christopher Dampier,Mathew Devall,Fredrick Schumacher,Marilena Melas,Gad Rennert,Mireia Obón-Santacana,Vicente Martín-Sánchez,Ferran Moratalla-Navarro,Jae Hwan Oh,Jeongseon Kim,Sun Ha Jee,Keum Ji Jung,Sun-Seog Kweon,Min-Ho Shin,Aesun Shin,Yoon-Ok Ahn,Dong-Hyun Kim,Isao Oze,Wanqing Wen,Keitaro Matsuo,Koichi Matsuda,Chizu Tanikawa,Zefang Ren,Yu-Tang Gao,Wei-Hua Jia,John Hopper,Mark Jenkins,Aung Ko Win,Rish Pai,Jane Figueiredo,Robert Haile,Steven Gallinger,Michael Woods,Polly Newcomb,David Duggan,Jeremy Cheadle,Richard Kaplan,Timothy Maughan,Rachel Kerr,David Kerr,Iva Kirac,Jan Böhm,Lukka-Pekka Mecklin,Pekka Jousilahti,Paul Knekt,Lauri Aaltonen,Harri Rissanen,Eero Pukkala,Johan Eriksson,Tatiana Cajuso,Ulrika Hänninen,Johanna Kondelin,Kimmo Palin,Tomas Tanskanen,Laura Renkonen-Sinisalo,Brent Zanke,Satu Männistö,Demetrius Albanes,Stephanie Weinstein,Edward Ruiz-Narvaez,Julie Palmer,Daniel Buchanan,Elizabeth Platz,Kala Visvanathan,Cornelia Ulrich,Erin Siegel,Stefanie Brezina,Andrea Gsur,Peter Campbell,Jenny Chang-Claude,Michael Hoffmeister,Hermann Brenner,Martha Slattery,John Potter,Konstantinos Tsilidis,Matthias Schulze,Marc Gunter,Neil Murphy,Antoni Castells,Sergi Castellví-Bel,Leticia Moreira,Volker Arndt,Anna Shcherbina,Mariana Stern,Bens Pardamean,Timothy Bishop,Graham Giles,Melissa Southey,Gregory Idos,Kevin McDonnell,Zomoroda Abu-Ful,Joel Greenson,Katerina Shulman,Flavio Lejbkowicz,Kenneth Offit,Yu-Ru Su,Robert Steinfelder,Temitope Keku,Bethany van Guelpen,Thomas Hudson,Heather Hampel,Rachel Pearlman,Sonja Berndt,Richard Hayes,Marie Elena Martinez,Sushma Thomas,Douglas Corley,Paul Pharoah,Susanna Larsson,Yun Yen,Heinz-Josef Lenz,Emily White,Li Li,Kimberly Doheny,Elizabeth Pugh,Tameka Shelford,Andrew Chan,Marcia Cruz-Correa,Annika Lindblom,David Hunter,Amit Joshi,Clemens Schafmayer,Peter Scacheri,Anshul Kundaje,Deborah Nickerson,Robert Schoen,Jochen Hampe,Zsofia Stadler,Pavel Vodicka,Ludmila Vodickova,Veronika Vymetalkova,Nickolas Papadopoulos,Chistopher Edlund,William Gauderman,Duncan Thomas,David Shibata,Amanda Toland,Sanford Markowitz,Andre Kim,Stephen Chanock,Franzel van Duijnhoven,Edith Feskens,Lori Sakoda,Manuela Gago-Dominguez,Alicja Wolk,Alessio Naccarati,Barbara Pardini,Liesel FitzGerald,Soo Chin Lee,Shuji Ogino,Stephanie Bien,Charles Kooperberg,Christopher Li,Yi Lin,Ross Prentice,Conghui Qu,Stéphane Bézieau,Catherine Tangen,Elaine Mardis,Taiki Yamaji,Norie Sawada,Motoki Iwasaki,Christopher Haiman,Loic Le Marchand,Anna Wu,Chenxu Qu,Caroline McNeil,Gerhard Coetzee,Caroline Hayward,Ian Deary,Sarah Harris,Evropi Theodoratou,Stuart Reid,Marion Walker,Li Yin Ooi,Victor Moreno,Graham Casey,Stephen Gruber,Ian Tomlinson,Wei Zheng,Malcolm Dunlop,Richard Houlston,Ulrike Peters

DOI: https://doi.org/10.1038/s41588-022-01222-9

IF: 30.8

2022-12-21

Nature Genetics

Abstract:Colorectal cancer (CRC) is a leading cause of mortality worldwide. We conducted a genome-wide association study meta-analysis of 100,204 CRC cases and 154,587 controls of European and east Asian ancestry, identifying 205 independent risk associations, of which 50 were unreported. We performed integrative genomic, transcriptomic and methylomic analyses across large bowel mucosa and other tissues. Transcriptome- and methylome-wide association studies revealed an additional 53 risk associations. We identified 155 high-confidence effector genes functionally linked to CRC risk, many of which had no previously established role in CRC. These have multiple different functions and specifically indicate that variation in normal colorectal homeostasis, proliferation, cell adhesion, migration, immunity and microbial interactions determines CRC risk. Crosstissue analyses indicated that over a third of effector genes most probably act outside the colonic mucosa. Our findings provide insights into colorectal oncogenesis and highlight potential targets across tissues for new CRC treatment and chemoprevention strategies.

genetics & heredity
Application of a 5-Tiered Scheme for Standardized Classification of 2,360 Unique Mismatch Repair Gene Variants in the InSiGHT Locus-Specific Database.

Bryony A Thompson,Amanda B Spurdle,John-Paul Plazzer,Marc S Greenblatt,Kiwamu Akagi,Fahd Al-Mulla,Bharati Bapat,Inge Bernstein,Gabriel Capellá,Johan T den Dunnen,Desiree du Sart,Aurelie Fabre,Michael P Farrell,Susan M Farrington,Ian M Frayling,Thierry Frebourg,David E Goldgar,Christopher D Heinen,Elke Holinski-Feder,Maija Kohonen-Corish,Kristina Lagerstedt Robinson,Suet Yi Leung,Alexandra Martins,Pal Moller,Monika Morak,Minna Nystrom,Paivi Peltomaki,Marta Pineda,Ming Qi,Rajkumar Ramesar,Lene Juel Rasmussen,Brigitte Royer-Pokora,Rodney J Scott,Rolf Sijmons,Sean V Tavtigian,Carli M Tops,Thomas Weber,Juul Wijnen,Michael O Woods,Finlay Macrae,Maurizio Genuardi,Adela Castillejo

DOI: https://doi.org/10.1038/ng.2854

IF: 30.8

2013-01-01

Nature Genetics

Abstract:The clinical classification of hereditary sequence variants identified in disease-related genes directly affects clinical management of patients and their relatives. The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a collaborative effort to develop, test and apply a standardized classification scheme to constitutional variants in the Lynch syndrome-associated genes MLH1, MSH2, MSH6 and PMS2. Unpublished data submission was encouraged to assist in variant classification and was recognized through microattribution. The scheme was refined by multidisciplinary expert committee review of the clinical and functional data available for variants, applied to 2,360 sequence alterations, and disseminated online. Assessment using validated criteria altered classifications for 66% of 12,006 database entries. Clinical recommendations based on transparent evaluation are now possible for 1,370 variants that were not obviously protein truncating from nomenclature. This large-scale endeavor will facilitate the consistent management of families suspected to have Lynch syndrome and demonstrates the value of multidisciplinary collaboration in the curation and classification of variants in public locus-specific databases.
Identification of metabolites of the novel anti-tumor drug candidate MDH-7 in rat urine by liquid chromatography coupled with triple quadrupole linear ion trap mass spectrometry.

Juan Li,Yu Chen,Yanyan Diao,Yingqian Su,Qingli Wang,Zhicun Yao,Tianxiang Yi,Wenting Jin,Dan Zhao,Caihong Wang,Mengru Liu,Hongmin Liu

DOI: https://doi.org/10.1002/rcm.7506

IF: 2.586

2016-04-15

Rapid Communications in Mass Spectrometry

Abstract:RATIONALE Our previous preliminary pharmacokinetic study demonstrated that the novel double pyrimidine tricyclic nucleoside MDH-7 in rats had a very short half-life (<30 min) after oral administration. As a result, the in vivo metabolic profile of MDH-7 should be investigated during early stages of drug development to better select drug candidates. METHODS In this study, a rapid method was developed to identify the metabolites of MDH-7 in rat urine by means of ultra-performance liquid chromatography (UPLC) coupled with electrospray ionization mass spectrometry (ESI-MS) using a triple quadrupole linear ion trap instrument. MDH-7 and its metabolites were detected and characterized by the combined use of the multiple reaction monitoring-information-dependent acquisition-enhanced product ion (MRM-IDA-EPI) mode and the precursor scan information-dependent acquisition-enhanced product ion (PREC-IDA-EPI) mode. RESULTS Ten novel metabolites of MDH-7 were identified and characterized in rat urine by LC/ESI-MS and collision-induced dissociation tandem mass spectrometry (CID-MS/MS) analyses. M1 was identified as 5-fluoro-N(4) -[(pentyloxy)carbonyl]cytosine; M2 and M3 were formed by hydroxylation products of M1. Metabolites M4-M10 were formed by a series of degradation reactions such as: deacetylation, hydroxylation, loss of the defluorocytosine base, oxidative-deamination, loss of the defluorouracil base, N-dealkylation and amide hydrolysis. CONCLUSIONS Based on the profiles of the metabolites, possible metabolic pathways of MDH-7 in rats were proposed for the first time. This study provides new and available information on the metabolism of MDH-7 which is very useful to further understand its in vivo metabolic fate. Copyright © 2016 John Wiley & Sons, Ltd.
Imputation and Subset-Based Association Analysis Across Different Cancer Types Identifies Multiple Independent Risk Loci in the TERT-CLPTM1L Region on Chromosome 5P15.33.

Zhaoming Wang,Bin Zhu,Mingfeng Zhang,Hemang Parikh,Jinping Jia,Charles C Chung,Joshua N Sampson,Jason W Hoskins,Amy Hutchinson,Laurie Burdette,Abdisamad Ibrahim,Christopher Hautman,Preethi S Raj,Christian C Abnet,Andrew A Adjei,Anders Ahlbom,Demetrius Albanes,Naomi E Allen,Christine B Ambrosone,Melinda Aldrich,Pilar Amiano,Christopher Amos,Ulrika Andersson,Gerald Andriole,Irene L Andrulis,Cecilia Arici,Alan A Arslan,Melissa A Austin,Dalsu Baris,Donald A Barkauskas,Bryan A Bassig,Laura E Beane Freeman,Christine D Berg,Sonja I Berndt,Pier Alberto Bertazzi,Richard B Biritwum,Amanda Black,William Blot,Heiner Boeing,Paolo Boffetta,Kelly Bolton,Marie-Christine Boutron-Ruault,Paige M Bracci,Paul Brennan,Louise A Brinton,Michelle Brotzman,H Bas Bueno-de-Mesquita,Julie E Buring,Mary Ann Butler,Qiuyin Cai,Geraldine Cancel-Tassin,Federico Canzian,Guangwen Cao,Neil E Caporaso,Alfredo Carrato,Tania Carreon,Angela Carta,Gee-Chen Chang,I-Shou Chang,Jenny Chang-Claude,Xu Che,Chien-Jen Chen,Chih-Yi Chen,Chung-Hsing Chen,Constance Chen,Kuan-Yu Chen,Yuh-Min Chen,Anand P Chokkalingam,Lisa W Chu,Francoise Clavel-Chapelon,Graham A Colditz,Joanne S Colt,David Conti,Michael B Cook,Victoria K Cortessis,E David Crawford,Olivier Cussenot,Faith G Davis,Immaculata De Vivo,Xiang Deng,Ti Ding,Colin P Dinney,Anna Luisa Di Stefano,W Ryan Diver,Eric J Duell,Joanne W Elena,Jin-Hu Fan,Heather Spencer Feigelson,Maria Feychting,Jonine D Figueroa,Adrienne M Flanagan,Joseph F Fraumeni,Neal D Freedman,Brooke L Fridley,Charles S Fuchs,Manuela Gago-Dominguez,Steven Gallinger,Yu-Tang Gao,Susan M Gapstur,Montserrat Garcia-Closas,Reina Garcia-Closas,Julie M Gastier-Foster,J Michael Gaziano,Daniela S Gerhard,Carol A Giffen,Graham G Giles,Elizabeth M Gillanders,Edward L Giovannucci,Michael Goggins,Nalan Gokgoz,Alisa M Goldstein,Carlos Gonzalez,Richard Gorlick,Mark H Greene,Myron Gross,H Barton Grossman,Robert Grubb,Jian Gu,Peng Guan,Christopher A Haiman,Goran Hallmans,Susan E Hankinson,Curtis C Harris,Patricia Hartge,Claudia Hattinger,Richard B Hayes,Qincheng He,Lee Helman,Brian E Henderson,Roger Henriksson,Judith Hoffman-Bolton,Chancellor Hohensee,Elizabeth A Holly,Yun-Chul Hong,Robert N Hoover,H Dean Hosgood,Chin-Fu Hsiao,Ann W Hsing,Chao Agnes Hsiung,Nan Hu,Wei Hu,Zhibin Hu,Ming-Shyan Huang,David J Hunter,Peter D Inskip,Hidemi Ito,Eric J Jacobs,Kevin B Jacobs,Mazda Jenab,Bu-Tian Ji,Christoffer Johansen,Mattias Johansson,Alison Johnson,Rudolf Kaaks,Ashish M Kamat,Aruna Kamineni,Margaret Karagas,Chand Khanna,Kay-Tee Khaw,Christopher Kim,In-Sam Kim,Jin Hee Kim,Yeul Hong Kim,Young-Chul Kim,Young Tae Kim,Chang Hyun Kang,Yoo Jin Jung,Cari M Kitahara,Alison P Klein,Robert Klein,Manolis Kogevinas,Woon-Puay Koh,Takashi Kohno,Laurence N Kolonel,Charles Kooperberg,Christian P Kratz,Vittorio Krogh,Hideo Kunitoh,Robert C Kurtz,Nilgun Kurucu,Qing Lan,Mark Lathrop,Ching C Lau,Fernando Lecanda,Kyoung-Mu Lee,Maxwell P Lee,Loic Le Marchand,Seth P Lerner,Donghui Li,Linda M Liao,Wei-Yen Lim,Dongxin Lin,Jie Lin,Sara Lindstrom,Martha S Linet,Jolanta Lissowska,Jianjun Liu,Börje Ljungberg,Josep Lloreta,Daru Lu,Jing Ma,Nuria Malats,Satu Mannisto,Neyssa Marina,Giuseppe Mastrangelo,Keitaro Matsuo,Katherine A McGlynn,Roberta McKean-Cowdin,Lorna H McNeill,Robert R McWilliams,Beatrice S Melin,Paul S Meltzer,James E Mensah,Xiaoping Miao,Dominique S Michaud,Alison M Mondul,Lee E Moore,Kenneth Muir,Shelley Niwa,Sara H Olson,Nick Orr,Salvatore Panico,Jae Yong Park,Alpa V Patel,Ana Patino-Garcia,Sofia Pavanello,Petra H M Peeters,Beata Peplonska,Ulrike Peters,Gloria M Petersen,Piero Picci,Malcolm C Pike,Stefano Porru,Jennifer Prescott,Xia Pu,Mark P Purdue,You-Lin Qiao,Preetha Rajaraman,Elio Riboli,Harvey A Risch,Rebecca J Rodabough,Nathaniel Rothman,Avima M Ruder,Jeong-Seon Ryu,Marc Sanson,Alan Schned,Fredrick R Schumacher,Ann G Schwartz,Kendra L Schwartz,Molly Schwenn,Katia Scotlandi,Adeline Seow,Consol Serra,Massimo Serra,Howard D Sesso,Gianluca Severi,Hongbing Shen,Min Shen,Sanjay Shete,Kouya Shiraishi,Xiao-Ou Shu,Afshan Siddiq,Luis Sierrasesumaga,Sabina Sierri,Alan Dart Loon Sihoe,Debra T Silverman,Matthias Simon,Melissa C Southey,Logan Spector,Margaret Spitz,Meir Stampfer,Par Stattin,Mariana C Stern,Victoria L Stevens,Rachael Z Stolzenberg-Solomon,Daniel O Stram,Sara S Strom,Wu-Chou Su,Malin Sund,Sook Whan Sung,Anthony Swerdlow,Wen Tan,Hideo Tanaka,Wei Tang,Ze-Zhang Tang,Adonina Tardon,Evelyn Tay,Philip R Taylor,Yao Tettey,David M Thomas,Roberto Tirabosco,Anne Tjonneland,Geoffrey S Tobias,Jorge R Toro,Ruth C Travis,Dimitrios Trichopoulos,Rebecca Troisi,Ann Truelove,Ying-Huang Tsai,Margaret A Tucker,Rosario Tumino,David Van Den Berg,Stephen K Van Den Eeden,Roel Vermeulen,Paolo Vineis,Kala Visvanathan,Ulla Vogel,Chaoyu Wang,Chengfeng Wang,Junwen Wang,Sophia S Wang,Elisabete Weiderpass,Stephanie J Weinstein,Nicolas Wentzensen,William Wheeler,Emily White,John K Wiencke,Alicja Wolk,Brian M Wolpin,Maria Pik Wong,Margaret Wrensch,Chen Wu,Tangchun Wu,Xifeng Wu,Yi-Long Wu,Jay S Wunder,Yong-Bing Xiang,Jun Xu,Hannah P Yang,Pan-Chyr Yang,Yasushi Yatabe,Yuanqing Ye,Edward D Yeboah,Zhihua Yin,Chen Ying,Chong-Jen Yu,Kai Yu,Jian-Min Yuan,Krista A Zanetti,Anne Zeleniuch-Jacquotte,Wei Zheng,Baosen Zhou,Lisa Mirabello,Sharon A Savage,Peter Kraft,Stephen J Chanock,Meredith Yeager,Maria Terese Landi,Jianxin Shi,Nilanjan Chatterjee,Laufey T Amundadottir

DOI: https://doi.org/10.1093/hmg/ddu363

IF: 5.1214

2014-01-01

Human Molecular Genetics

Abstract:Genome-wide association studies (GWAS) have mapped risk alleles for at least 10 distinct cancers to a small region of 63 000 bp on chromosome 5p15.33. This region harbors the TERT and CLPTM1L genes; the former encodes the catalytic subunit of telomerase reverse transcriptase and the latter may play a role in apoptosis. To investigate further the genetic architecture of common susceptibility alleles in this region, we conducted an agnostic subset-based meta-analysis (association analysis based on subsets) across six distinct cancers in 34 248 cases and 45 036 controls. Based on sequential conditional analysis, we identified as many as six independent risk loci marked by common single-nucleotide polymorphisms: five in the TERT gene (Region 1: rs7726159, P = 2.10 × 10(-39); Region 3: rs2853677, P = 3.30 × 10(-36) and PConditional = 2.36 × 10(-8); Region 4: rs2736098, P = 3.87 × 10(-12) and PConditional = 5.19 × 10(-6), Region 5: rs13172201, P = 0.041 and PConditional = 2.04 × 10(-6); and Region 6: rs10069690, P = 7.49 × 10(-15) and PConditional = 5.35 × 10(-7)) and one in the neighboring CLPTM1L gene (Region 2: rs451360; P = 1.90 × 10(-18) and PConditional = 7.06 × 10(-16)). Between three and five cancers mapped to each independent locus with both risk-enhancing and protective effects. Allele-specific effects on DNA methylation were seen for a subset of risk loci, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants on 5p15.33. Our results provide strong support for extensive pleiotropy across this region of 5p15.33, to an extent not previously observed in other cancer susceptibility loci.
Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database

Pål Møller,Toni T Seppälä,Inge Bernstein,Elke Holinski-Feder,Paulo Sala,D Gareth Evans,Annika Lindblom,Finlay Macrae,Ignacio Blanco,Rolf H Sijmons,Jacqueline Jeffries,Hans F A Vasen,John Burn,Sigve Nakken,Eivind Hovig,Einar Andreas Rødland,Kukatharmini Tharmaratnam,Wouter H de Vos Tot Nederveen Cappel,James Hill,Juul T Wijnen,Mark A Jenkins,Kate Green,Fiona Lalloo,Lone Sunde,Miriam Mints,Lucio Bertario,Marta Pineda,Matilde Navarro,Monika Morak,Laura Renkonen-Sinisalo,Mev Dominguez Valentin,Ian M Frayling,John-Paul Plazzer,Kirsi Pylvanainen,Maurizio Genuardi,Jukka-Pekka Mecklin,Gabriela Moeslein,Julian R Sampson,Gabriel Capella,Mallorca Group

DOI: https://doi.org/10.1136/gutjnl-2017-314057

IF: 24.5

Gut

Abstract:Background: Most patients with path_MMR gene variants (Lynch syndrome (LS)) now survive both their first and subsequent cancers, resulting in a growing number of older patients with LS for whom limited information exists with respect to cancer risk and survival. Objective and design: This observational, international, multicentre study aimed to determine prospectively observed incidences of cancers and survival in path_MMR carriers up to 75 years of age. Results: 3119 patients were followed for a total of 24 475 years. Cumulative incidences at 75 years (risks) for colorectal cancer were 46%, 43% and 15% in path_MLH1, path_MSH2 and path_MSH6 carriers; for endometrial cancer 43%, 57% and 46%; for ovarian cancer 10%, 17% and 13%; for upper gastrointestinal (gastric, duodenal, bile duct or pancreatic) cancers 21%, 10% and 7%; for urinary tract cancers 8%, 25% and 11%; for prostate cancer 17%, 32% and 18%; and for brain tumours 1%, 5% and 1%, respectively. Ovarian cancer occurred mainly premenopausally. By contrast, upper gastrointestinal, urinary tract and prostate cancers occurred predominantly at older ages. Overall 5-year survival for prostate cancer was 100%, urinary bladder 93%, ureter 85%, duodenum 67%, stomach 61%, bile duct 29%, brain 22% and pancreas 0%. Path_PMS2 carriers had lower risk for cancer. Conclusion: Carriers of different path_MMR variants exhibit distinct patterns of cancer risk and survival as they age. Risk estimates for counselling and planning of surveillance and treatment should be tailored to each patient's age, gender and path_MMR variant. We have updated our open-access website www.lscarisk.org to facilitate this.
Identification of 12 New Susceptibility Loci for Different Histotypes of Epithelial Ovarian Cancer

Catherine M Phelan,Karoline B Kuchenbaecker,Jonathan P Tyrer,Siddhartha P Kar,Kate Lawrenson,Stacey J Winham,Joe Dennis,Ailith Pirie,Marjorie J Riggan,Ganna Chornokur,Madalene A Earp,Paulo C Lyra Jr,Janet M Lee,Simon Coetzee,Jonathan Beesley,Lesley McGuffog,Penny Soucy,Ed Dicks,Andrew Lee,Daniel Barrowdale,Julie Lecarpentier,Goska Leslie,Cora M Aalfs,Katja K H Aben,Marcia Adams,Julian Adlard,Irene L Andrulis,Hoda Anton-Culver,Natalia Antonenkova,Gerasimos Aravantinos,Norbert Arnold,Banu K Arun,Brita Arver,Jacopo Azzollini,Judith Balmaña,Susana N Banerjee,Laure Barjhoux,Rosa B Barkardottir,Yukie Bean,Matthias W Beckmann,Alicia Beeghly-Fadiel,Javier Benitez,Marina Bermisheva,Marcus Q Bernardini,Michael J Birrer,Line Bjorge,Amanda Black,Kenneth Blankstein,Marinus J Blok,Clara Bodelon,Natalia Bogdanova,Anders Bojesen,Bernardo Bonanni,Åke Borg,Angela R Bradbury,James D Brenton,Carole Brewer,Louise Brinton,Per Broberg,Angela Brooks-Wilson,Fiona Bruinsma,Joan Brunet,Bruno Buecher,Ralf Butzow,Saundra S Buys,Trinidad Caldes,Maria A Caligo,Ian Campbell,Rikki Cannioto,Michael E Carney,Terence Cescon,Salina B Chan,Jenny Chang-Claude,Stephen Chanock,Xiao Qing Chen,Yoke-Eng Chiew,Jocelyne Chiquette,Wendy K Chung,Kathleen B M Claes,Thomas Conner,Linda S Cook,Jackie Cook,Daniel W Cramer,Julie M Cunningham,Aimee A D'Aloisio,Mary B Daly,Francesca Damiola,Sakaeva Dina Damirovna,Agnieszka Dansonka-Mieszkowska,Fanny Dao,Rosemarie Davidson,Anna DeFazio,Capucine Delnatte,Kimberly F Doheny,Orland Diez,Yuan Chun Ding,Jennifer Anne Doherty,Susan M Domchek,Cecilia M Dorfling,Thilo Dörk,Laure Dossus,Mercedes Duran,Matthias Dürst,Bernd Dworniczak,Diana Eccles,Todd Edwards,Ros Eeles,Ursula Eilber,Bent Ejlertsen,Arif B Ekici,Steve Ellis,Mingajeva Elvira,Kevin H Eng,Christoph Engel,D Gareth Evans,Peter A Fasching,Sarah Ferguson,Sandra Fert Ferrer,James M Flanagan,Zachary C Fogarty,Renée T Fortner,Florentia Fostira,William D Foulkes,George Fountzilas,Brooke L Fridley,Tara M Friebel,Eitan Friedman,Debra Frost,Patricia A Ganz,Judy Garber,María J García,Vanesa Garcia-Barberan,Andrea Gehrig,Aleksandra Gentry-Maharaj,Anne-Marie Gerdes,Graham G Giles,Rosalind Glasspool,Gord Glendon,Andrew K Godwin,David E Goldgar,Teodora Goranova,Martin Gore,Mark H Greene,Jacek Gronwald,Stephen Gruber,Eric Hahnen,Christopher A Haiman,Niclas Håkansson,Ute Hamann,Thomas V O Hansen,Patricia A Harrington,Holly R Harris,Jan Hauke,Alexander Hein,Alex Henderson,Michelle A T Hildebrandt,Peter Hillemanns,Shirley Hodgson,Claus K Høgdall,Estrid Høgdall,Frans B L Hogervorst,Helene Holland,Maartje J Hooning,Karen Hosking,Ruea-Yea Huang,Peter J Hulick,Jillian Hung,David J Hunter,David G Huntsman,Tomasz Huzarski,Evgeny N Imyanitov,Claudine Isaacs,Edwin S Iversen,Louise Izatt,Angel Izquierdo,Anna Jakubowska,Paul James,Ramunas Janavicius,Mats Jernetz,Allan Jensen,Uffe Birk Jensen,Esther M John,Sharon Johnatty,Michael E Jones,Päivi Kannisto,Beth Y Karlan,Anthony Karnezis,Karin Kast,Catherine J Kennedy,Elza Khusnutdinova,Lambertus A Kiemeney,Johanna I Kiiski,Sung-Won Kim,Susanne K Kjaer,Martin Köbel,Reidun K Kopperud,Torben A Kruse,Jolanta Kupryjanczyk,Ava Kwong,Yael Laitman,Diether Lambrechts,Nerea Larrañaga,Melissa C Larson,Conxi Lazaro,Nhu D Le,Loic Le Marchand,Jong Won Lee,Shashikant B Lele,Arto Leminen,Dominique Leroux,Jenny Lester,Fabienne Lesueur,Douglas A Levine,Dong Liang,Clemens Liebrich,Jenna Lilyquist,Loren Lipworth,Jolanta Lissowska,Karen H Lu,Jan Lubinński,Craig Luccarini,Lene Lundvall,Phuong L Mai,Gustavo Mendoza-Fandiño,Siranoush Manoukian,Leon F A G Massuger,Taymaa May,Sylvie Mazoyer,Jessica N McAlpine,Valerie McGuire,John R McLaughlin,Iain McNeish,Hanne Meijers-Heijboer,Alfons Meindl,Usha Menon,Arjen R Mensenkamp,Melissa A Merritt,Roger L Milne,Gillian Mitchell,Francesmary Modugno,Joanna Moes-Sosnowska,Melissa Moffitt,Marco Montagna,Kirsten B Moysich,Anna Marie Mulligan,Jacob Musinsky,Katherine L Nathanson,Lotte Nedergaard,Roberta B Ness,Susan L Neuhausen,Heli Nevanlinna,Dieter Niederacher,Robert L Nussbaum,Kunle Odunsi,Edith Olah,Olufunmilayo I Olopade,Håkan Olsson,Curtis Olswold,David M O'Malley,Kai-ren Ong,N Charlotte Onland-Moret,Nicholas Orr,Sandra Orsulic,Ana Osorio,Domenico Palli,Laura Papi,Tjoung-Won Park-Simon,James Paul,Celeste L Pearce,Inge Søkilde Pedersen,Petra H M Peeters,Bernard Peissel,Ana Peixoto,Tanja Pejovic,Liisa M Pelttari,Jennifer B Permuth,Paolo Peterlongo,Lidia Pezzani,Georg Pfeiler,Kelly-Anne Phillips,Marion Piedmonte,Malcolm C Pike,Anna M Piskorz,Samantha R Poblete,Timea Pocza,Elizabeth M Poole,Bruce Poppe,Mary E Porteous,Fabienne Prieur,Darya Prokofyeva,Elizabeth Pugh,Miquel Angel Pujana,Pascal Pujol,Paolo Radice,Johanna Rantala,Christine Rappaport-Fuerhauser,Gad Rennert,Kerstin Rhiem,Patricia Rice,Andrea Richardson,Mark Robson,Gustavo C Rodriguez,Cristina Rodríguez-Antona,Jane Romm,Matti A Rookus,Mary Anne Rossing,Joseph H Rothstein,Anja Rudolph,Ingo B Runnebaum,Helga B Salvesen,Dale P Sandler,Minouk J Schoemaker,Leigha Senter,V Wendy Setiawan,Gianluca Severi,Priyanka Sharma,Tameka Shelford,Nadeem Siddiqui,Lucy E Side,Weiva Sieh,Christian F Singer,Hagay Sobol,Honglin Song,Melissa C Southey,Amanda B Spurdle,Zsofia Stadler,Doris Steinemann,Dominique Stoppa-Lyonnet,Lara E Sucheston-Campbell,Grzegorz Sukiennicki,Rebecca Sutphen,Christian Sutter,Anthony J Swerdlow,Csilla I Szabo,Lukasz Szafron,Yen Y Tan,Jack A Taylor,Muy-Kheng Tea,Manuel R Teixeira,Soo-Hwang Teo,Kathryn L Terry,Pamela J Thompson,Liv Cecilie Vestrheim Thomsen,Darcy L Thull,Laima Tihomirova,Anna V Tinker,Marc Tischkowitz,Silvia Tognazzo,Amanda Ewart Toland,Alicia Tone,Britton Trabert,Ruth C Travis,Antonia Trichopoulou,Nadine Tung,Shelley S Tworoger,Anne M van Altena,David Van Den Berg,Annemarie H van der Hout,Rob B van der Luijt,Mattias Van Heetvelde,Els Van Nieuwenhuysen,Elizabeth J van Rensburg,Adriaan Vanderstichele,Raymonda Varon-Mateeva,Ana Vega,Digna Velez Edwards,Ignace Vergote,Robert A Vierkant,Joseph Vijai,Athanassios Vratimos,Lisa Walker,Christine Walsh,Dorothea Wand,Shan Wang-Gohrke,Barbara Wappenschmidt,Penelope M Webb,Clarice R Weinberg,Jeffrey N Weitzel,Nicolas Wentzensen,Alice S Whittemore,Juul T Wijnen,Lynne R Wilkens,Alicja Wolk,Michelle Woo,Xifeng Wu,Anna H Wu,Hannah Yang,Drakoulis Yannoukakos,Argyrios Ziogas,Kristin K Zorn,Steven A Narod,Douglas F Easton,Christopher I Amos,Joellen M Schildkraut,Susan J Ramus,Laura Ottini,Marc T Goodman,Sue K Park,Linda E Kelemen,Harvey A Risch,Mads Thomassen,Kenneth Offit,Jacques Simard,Rita Katharina Schmutzler,Dennis Hazelett,Alvaro N Monteiro,Fergus J Couch,Andrew Berchuck,Georgia Chenevix-Trench,Ellen L Goode,Thomas A Sellers,Simon A Gayther,Antonis C Antoniou,Paul D P Pharoah

DOI: https://doi.org/10.1038/ng.3826

IF: 30.8

2017-01-01

Nature Genetics

Abstract:To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.
Identification of Six New Susceptibility Loci for Invasive Epithelial Ovarian Cancer.

Karoline B Kuchenbaecker,Susan J Ramus,Jonathan Tyrer,Andrew Lee,Howard C Shen,Jonathan Beesley,Kate Lawrenson,Lesley McGuffog,Sue Healey,Janet M Lee,Tassja J Spindler,Yvonne G Lin,Tanja Pejovic,Yukie Bean,Qiyuan Li,Simon Coetzee,Dennis Hazelett,Alexander Miron,Melissa Southey,Mary Beth Terry,David E Goldgar,Saundra S Buys,Ramunas Janavicius,Cecilia M Dorfling,Elizabeth J van Rensburg,Susan L Neuhausen,Yuan Chun Ding,Thomas V O Hansen,Lars Jønson,Anne-Marie Gerdes,Bent Ejlertsen,Daniel Barrowdale,Joe Dennis,Javier Benitez,Ana Osorio,Maria Jose Garcia,Ian Komenaka,Jeffrey N Weitzel,Pamela Ganschow,Paolo Peterlongo,Loris Bernard,Alessandra Viel,Bernardo Bonanni,Bernard Peissel,Siranoush Manoukian,Paolo Radice,Laura Papi,Laura Ottini,Florentia Fostira,Irene Konstantopoulou,Judy Garber,Debra Frost,Jo Perkins,Radka Platte,Steve Ellis,EMBRACE,Andrew K Godwin,Rita Katharina Schmutzler,Alfons Meindl,Christoph Engel,Christian Sutter,Olga M Sinilnikova,GEMO Study Collaborators,Francesca Damiola,Sylvie Mazoyer,Dominique Stoppa-Lyonnet,Kathleen Claes,Kim De Leeneer,Judy Kirk,Gustavo C Rodriguez,Marion Piedmonte,David M O'Malley,Miguel de la Hoya,Trinidad Caldes,Kristiina Aittomäki,Heli Nevanlinna,J Margriet Collée,Matti A Rookus,Jan C Oosterwijk,Breast Cancer Family Registry,Laima Tihomirova,Nadine Tung,Ute Hamann,Claudine Isaccs,Marc Tischkowitz,Evgeny N Imyanitov,Maria A Caligo,Ian G Campbell,Frans B L Hogervorst,HEBON,Edith Olah,Orland Diez,Ignacio Blanco,Joan Brunet,Conxi Lazaro,Miquel Angel Pujana,Anna Jakubowska,Jacek Gronwald,Jan Lubinski,Grzegorz Sukiennicki,Rosa B Barkardottir,Marie Plante,Jacques Simard,Penny Soucy,Marco Montagna,Silvia Tognazzo,Manuel R Teixeira,KConFab Investigators,Vernon S Pankratz,Xianshu Wang,Noralane Lindor,Csilla I Szabo,Noah Kauff,Joseph Vijai,Carol A Aghajanian,Georg Pfeiler,Andreas Berger,Christian F Singer,Muy-Kheng Tea,Catherine M Phelan,Mark H Greene,Phuong L Mai,Gad Rennert,Anna Marie Mulligan,Sandrine Tchatchou,Irene L Andrulis,Gord Glendon,Amanda Ewart Toland,Uffe Birk Jensen,Torben A Kruse,Mads Thomassen,Anders Bojesen,Jamal Zidan,Eitan Friedman,Yael Laitman,Maria Soller,Annelie Liljegren,Brita Arver,Zakaria Einbeigi,Marie Stenmark-Askmalm,Olufunmilayo I Olopade,Robert L Nussbaum,Timothy R Rebbeck,Katherine L Nathanson,Susan M Domchek,Karen H Lu,Beth Y Karlan,Christine Walsh,Jenny Lester,Australian Cancer Study (Ovarian Cancer Investigators),Australian Ovarian Cancer Study Group,Alexander Hein,Arif B Ekici,Matthias W Beckmann,Peter A Fasching,Diether Lambrechts,Els Van Nieuwenhuysen,Ignace Vergote,Sandrina Lambrechts,Ed Dicks,Jennifer A Doherty,Kristine G Wicklund,Mary Anne Rossing,Anja Rudolph,Jenny Chang-Claude,Shan Wang-Gohrke,Ursula Eilber,Kirsten B Moysich,Kunle Odunsi,Lara Sucheston,Shashi Lele,Lynne R Wilkens,Marc T Goodman,Pamela J Thompson,Yurii B Shvetsov,Ingo B Runnebaum,Matthias Dürst,Peter Hillemanns,Thilo Dörk,Natalia Antonenkova,Natalia Bogdanova,Arto Leminen,Liisa M Pelttari,Ralf Butzow,Francesmary Modugno,Joseph L Kelley,Robert P Edwards,Roberta B Ness,Andreas du Bois,Florian Heitz,Ira Schwaab,Philipp Harter,Keitaro Matsuo,Satoyo Hosono,Sandra Orsulic,Allan Jensen,Susanne Kruger Kjaer,Estrid Hogdall,Hanis Nazihah Hasmad,Mat Adenan Noor Azmi,Soo-Hwang Teo,Yin-Ling Woo,Brooke L Fridley,Ellen L Goode,Julie M Cunningham,Robert A Vierkant,Fiona Bruinsma,Graham G Giles,Dong Liang,Michelle A T Hildebrandt,Xifeng Wu,Douglas A Levine,Maria Bisogna,Andrew Berchuck,Edwin S Iversen,Joellen M Schildkraut,Patrick Concannon,Rachel Palmieri Weber,Daniel W Cramer,Kathryn L Terry,Elizabeth M Poole,Shelley S Tworoger,Elisa V Bandera,Irene Orlow,Sara H Olson,Camilla Krakstad,Helga B Salvesen,Ingvild L Tangen,Line Bjorge,Anne M van Altena,Katja K H Aben,Lambertus A Kiemeney,Leon F A G Massuger,Melissa Kellar,Angela Brooks-Wilson,Linda E Kelemen,Linda S Cook,Nhu D Le,Cezary Cybulski,Hannah Yang,Jolanta Lissowska,Louise A Brinton,Nicolas Wentzensen,Claus Hogdall,Lene Lundvall,Lotte Nedergaard,Helen Baker,Honglin Song,Diana Eccles,Ian McNeish,James Paul,Karen Carty,Nadeem Siddiqui,Rosalind Glasspool,Alice S Whittemore,Joseph H Rothstein,Valerie McGuire,Weiva Sieh,Bu-Tian Ji,Wei Zheng,Xiao-Ou Shu,Yu-Tang Gao,Barry Rosen,Harvey A Risch,John R McLaughlin,Steven A Narod,Alvaro N Monteiro,Ann Chen,Hui-Yi Lin,Jenny Permuth-Wey,Thomas A Sellers,Ya-Yu Tsai,Zhihua Chen,Argyrios Ziogas,Hoda Anton-Culver,Aleksandra Gentry-Maharaj,Usha Menon,Patricia Harrington,Alice W Lee,Anna H Wu,Celeste L Pearce,Gerry Coetzee,Malcolm C Pike,Agnieszka Dansonka-Mieszkowska,Agnieszka Timorek,Iwona K Rzepecka,Jolanta Kupryjanczyk,Matt Freedman,Houtan Noushmehr,Douglas F Easton,Kenneth Offit,Fergus J Couch,Simon Gayther,Paul P Pharoah,Antonis C Antoniou,Georgia Chenevix-Trench,Consortium of Investigators of Modifiers of BRCA and BRCA

DOI: https://doi.org/10.1038/ng.3185

IF: 30.8

2015-01-01

Nature Genetics

Abstract:Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8). Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
The N-methyl-d-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine

G. Farfel,G. Vosmer,L. Seiden

DOI: https://doi.org/10.1016/0006-8993(92)91460-V

IF: 3.61

1992-11-06

Brain Research

Abstract:
MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4.

Qiang Wang,Zheng Huang,Huiling Xue,C. Jin,X. Ju,J. Han,Ye-Guang Chen

DOI: https://doi.org/10.1182/BLOOD-2007-05-092718

IF: 20.3

2008-01-15

Blood

Abstract:MicroRNAs have been suggested to modulate a variety of cellular events. Here we report that miR-24 regulates erythroid differentiation by influencing the expression of human activin type I receptor ALK4 (hALK4). Ectopic expression of miR-24 reduces the mRNA and protein levels of hALK4 by targeting the 3'-untranslated region of hALK4 mRNA and interferes with activin-induced Smad2 phosphorylation and reporter expression. Furthermore, miR-24 represses the activin-mediated accumulation of hemoglobin, an erythroid differentiation marker, in erythroleukemic K562 cells and decreases erythroid colony-forming and burst-forming units of CD34+ hematopoietic progenitor cells. ALK4 expression is inversely correlated with miR-24 expression during the early stages of erythroid differentiation, and the forced expression of miR-24 leads to a delay of activin-induced maturation of hematopoietic progenitor cells in liquid culture. Thus, our findings define a regulation mode of miR-24 on erythropoiesis by impeding ALK4 expression.

Pulmonary embolism following placement of a Greenfield Filter.

Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome

Genome-wide association study of germline variants and breast cancer-specific mortality

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

The Prevalence of Germline Mutations in Chinese Colorectal Cancer Patients with Mismatch Repair Deficiency.

No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer.

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study

Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes - an EHTG, PLSD position statement

Cancer Risks for PMS2-Associated Lynch Syndrome.

Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

Application of a 5-Tiered Scheme for Standardized Classification of 2,360 Unique Mismatch Repair Gene Variants in the InSiGHT Locus-Specific Database.

Identification of metabolites of the novel anti-tumor drug candidate MDH-7 in rat urine by liquid chromatography coupled with triple quadrupole linear ion trap mass spectrometry.

Imputation and Subset-Based Association Analysis Across Different Cancer Types Identifies Multiple Independent Risk Loci in the TERT-CLPTM1L Region on Chromosome 5P15.33.

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database

Identification of 12 New Susceptibility Loci for Different Histotypes of Epithelial Ovarian Cancer

Identification of Six New Susceptibility Loci for Invasive Epithelial Ovarian Cancer.

The N-methyl-d-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine

MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4.